journal
Journals Ontario Health Technology Asse...

Ontario Health Technology Assessment Series

https://read.qxmd.com/read/38028531/robotic-assisted-partial-nephrectomy-for-kidney-cancer-a-health-technology-assessment
#1
JOURNAL ARTICLE
(no author information available yet)
BACKGROUND: Robotic-assisted surgery has been used in Ontario hospitals for over a decade, but there is no public funding for the robotic systems or the disposables required to perform robotic-assisted surgeries ("robotics disposables"). We conducted a health technology assessment of robotic-assisted partial nephrectomy for the treatment of kidney cancer (RAPN). Nephrectomy may be radical (the surgical removal of an entire kidney, nearby adrenal gland and lymph nodes, and other surrounding tissue) or partial (the surgical removal of part of a kidney or a kidney tumour)...
2023: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/38026449/robotic-assisted-hysterectomy-for-endometrial-cancer-in-people-with-obesity-a-health-technology-assessment
#2
JOURNAL ARTICLE
(no author information available yet)
BACKGROUND: Robotic-assisted surgery has been used in Ontario hospitals for over a decade, but there is no public funding for the robotic systems or the disposables required to perform robotic-assisted surgeries ("robotics disposables"). We conducted a health technology assessment of robotic-assisted hysterectomy (RH) for the treatment of endometrial cancer in people with obesity. Our assessment included an evaluation of the effectiveness, safety, and cost-effectiveness of RH, as well as the 5-year budget impact for the Ontario Ministry of Health of publicly funding RH...
2023: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/37772268/first-trimester-screening-program-for-the-risk-of-pre-eclampsia-using-a-multiple-marker-algorithm-a-health-technology-assessment
#3
JOURNAL ARTICLE
(no author information available yet)
BACKGROUND: Pre-eclampsia is when high blood pressure develops after 20 weeks of pregnancy and either proteinuria, maternal end-organ dysfunction, or uteroplacental dysfunction causing fetal growth restriction also develops. The Fetal Medicine Foundation has created an algorithm ("the FMF algorithm") that uses maternal factors in combination with biophysical and biochemical markers to identify people at high risk for pre-eclampsia so that they can been offered acetylsalicylic acid (Aspirin) as a preventive measure...
2023: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/37637488/carrier-screening-programs-for-cystic-fibrosis-fragile-x-syndrome-hemoglobinopathies-and-thalassemia-and-spinal-muscular-atrophy-a-health-technology-assessment
#4
JOURNAL ARTICLE
(no author information available yet)
BACKGROUND: We conducted a health technology assessment to evaluate the safety, effectiveness, and cost-effectiveness of carrier screening programs for cystic fibrosis (CF), fragile X syndrome (FXS), hemoglobinopathies and thalassemia, and spinal muscular atrophy (SMA) in people who are considering a pregnancy or who are pregnant. We also evaluated the budget impact of publicly funding carrier screening programs, and patient preferences and values. METHODS: We performed a systematic literature search of the clinical evidence...
2023: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/37637244/homologous-recombination-deficiency-testing-to-inform-patient-decisions-about-niraparib-maintenance-therapy-for-high-grade-serous-or-endometrioid-epithelial-ovarian-cancer-a-health-technology-assessment
#5
JOURNAL ARTICLE
(no author information available yet)
BACKGROUND: Ovarian cancer affects the cells of the ovaries, and epithelial cancer is the most common type of malignant ovarian cancer. The homologous recombination repair pathway enables error-free repair of DNA double-strand breaks. Damage of key genes associated with this pathway leads to homologous recombination deficiency (HRD), which results in unrepaired DNA and can lead to cancer. Tumours with HRD are believed to be sensitive to treatment with poly-adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitors, such as niraparib...
2023: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/37284279/placental-growth-factor-plgf-based-biomarker-testing-to-help-diagnose-pre-eclampsia-in-people-with-suspected-pre-eclampsia-a-health-technology-assessment
#6
JOURNAL ARTICLE
(no author information available yet)
BACKGROUND: Pre-eclampsia is a potentially serious condition affecting up to 5% of pregnancies, most frequently after 20 weeks' gestation. Placental growth factor (PlGF)-based tests measure either the blood level of PlGF or the ratio of soluble fms-like tyrosine kinase-1 (sFlt-1) to PlGF. They are intended to complement standard clinical assessment to help diagnose pre-eclampsia in people with suspected pre-eclampsia. We conducted a health technology assessment of PlGF-based biomarker testing as an adjunct to standard clinical assessment to help diagnose pre-eclampsia in pregnant people with suspected pre-eclampsia, which included an evaluation of diagnostic accuracy, clinical utility, cost-effectiveness, the budget impact of publicly funding PlGF-based biomarker testing, and an assessment of preferences and values...
2023: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/37284228/wire-free-nonradioactive-localization-techniques-to-guide-surgical-excision-of-nonpalpable-breast-tumours-a-health-technology-assessment
#7
JOURNAL ARTICLE
(no author information available yet)
BACKGROUND: The current standard treatment for nonpalpable breast tumours is surgical excision; however, it is nearly impossible to locate these small masses during surgery. Therefore, a marker must be implanted into the abnormal tissue under mammography or ultrasound guidance prior to surgery to guide the surgeon to the location of the tumour. Two techniques to localize nonpalpable breast tumours are currently used in Ontario: wire-guided localization and radioactive seed localization...
2023: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/36818453/mechanical-thrombectomy-for-acute-and-subacute-blocked-arteries-and-veins-in-the-lower-limbs-a-health-technology-assessment
#8
JOURNAL ARTICLE
(no author information available yet)
BACKGROUND: A blockage to the blood vessels in the lower extremities may cause pain and discomfort. If left unmanaged, it may lead to amputation or chronic disability, such as in the form of post-thrombotic syndrome. We conducted a health technology assessment of mechanical thrombectomy (MT) devices, which are proposed to remove a blood clot, which may form in the arteries or veins of the lower legs. This evaluation considered blockages in the veins and arteries separately, and included an evaluation of effectiveness, safety, cost-effectiveness, the budget impact of publicly funding MT for lower limb blockages, patient preferences and values, and clinical and health system stakeholders' perspectives...
2023: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/36160757/pre-surgical-nasal-decolonization-of-staphylococcus-aureus-a-health-technology-assessment
#9
REVIEW
(no author information available yet)
BACKGROUND: Staphylococcus aureus (S. aureus) is the most common cause of surgical site infections, and the nose is the most common site for S. aureus colonization. Pre-surgical (in the days prior to surgery) nasal decolonization of S. aureus may reduce the bacterial load and prevent the organisms from being transferred to the surgical site, thus reducing the risk of surgical site infection. We conducted a health technology assessment of nasal decolonization of S. aureus (including methicillin-susceptible and methicillin-resistant strains) with or without topical antiseptic body wash to prevent surgical site infection in patients undergoing scheduled surgery, which included an evaluation of effectiveness, safety, cost-effectiveness, the budget impact of publicly funding nasal decolonization of S...
2022: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/36158868/genetic-testing-for-familial-hypercholesterolemia-health-technology-assessment
#10
JOURNAL ARTICLE
(no author information available yet)
Background: Familial hypercholesterolemia (FH) is an inherited disorder characterized by abnormally elevated low-density lipoprotein (LDL) cholesterol serum levels from birth, which increases the risk of premature atherosclerotic cardiovascular disease. Genetic testing is a type of a medical test that looks for changes in genes or chromosome structure to discover genetic differences, anomalies, or mutations that may prove pathological. It is regarded as the gold standard for screening and diagnosing FH...
2022: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/35591972/molecular-testing-for-thyroid-nodules-of-indeterminate-cytology-a-health-technology-assessment
#11
JOURNAL ARTICLE
(no author information available yet)
BACKGROUND: The thyroid is a gland in the lower neck that is responsible for secreting hormones related to growth and metabolism. A cancer growth in the thyroid can spread to other parts of the body, but most thyroid nodules (growths) are benign, and some types of thyroid cancer are nonaggressive and can be managed with active surveillance only. We conducted a health technology assessment of molecular testing in people with thyroid nodules of indeterminate cytology, which included an evaluation of diagnostic accuracy, clinical utility, cost-effectiveness, the budget impact of publicly funding molecular testing, and patient preferences and values...
2022: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/34527087/internet-delivered-cognitive-behavioural-therapy-for-post-traumatic-stress-disorder-or-acute-stress-disorder-a-health-technology-assessment
#12
JOURNAL ARTICLE
(no author information available yet)
Background: Post-traumatic stress disorder (PTSD) and acute stress disorder (ASD) are mental health conditions that may emerge following a frightening or traumatic event in a person's life. We conducted a health technology assessment of internet-delivered cognitive behavioural therapy (iCBT) for adults with PTSD or ASD, which included an evaluation of effectiveness, safety, cost-effectiveness, the budget impact of publicly funding iCBT for PTSD or ADS, and patient preferences and values...
2021: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/34484488/-dpyd-genotyping-in-patients-who-have-planned-cancer-treatment-with-fluoropyrimidines-a-health-technology-assessment
#13
REVIEW
(no author information available yet)
Background: Fluoropyrimidine drugs (such as 5-fluorouracil and capecitabine) are used to treat different types of cancer. However, these drugs may cause severe toxicity in about 10% to 40% of patients. A deficiency in the dihydropyrimidine dehydrogenase (DPD) enzyme, encoded by the DPYD gene, increases the risk of severe toxicity. DPYD genotyping aims to identify variants that lead to DPD deficiency and may help to identify people who are at higher risk of developing severe toxicity, allowing their treatment to be modified before it begins...
2021: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/34484487/multi-gene-pharmacogenomic-testing-that-includes-decision-support-tools-to-guide-medication-selection-for-major-depression-a-health-technology-assessment
#14
JOURNAL ARTICLE
(no author information available yet)
Background: Major depression is a substantial public health concern that can affect personal relationships, reduce people's ability to go to school or work, and lead to social isolation. Multi-gene pharmacogenomic testing that includes decision-support tools can help predict which depression medications and dosages are most likely to result in a strong response to treatment or to have the lowest risk of adverse events on the basis of people's genes.We conducted a health technology assessment of multi-gene pharmacogenomic testing that includes decision-support tools for people with major depression...
2021: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/34484486/enhanced-visualization-methods-for-first-transurethral-resection-of-bladder-tumour-in-suspected-non-muscle-invasive-bladder-cancer-a-health-technology-assessment
#15
JOURNAL ARTICLE
(no author information available yet)
Background: Bladder cancer begins in the innermost lining of the bladder wall and, on histological examination, is classified as one of two types: non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer. Transurethral resection of bladder tumour (TURBT) is the standard treatment for people with NMIBC, but the high rate of cancer recurrence after first TURBT is a challenge that physicians and patients face. Tumours seen during follow-up may have been missed or incompletely resected during first TURBT...
2021: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/34484485/stance-control-knee-ankle-foot-orthoses-for-people-with-knee-instability-a-health-technology-assessment
#16
JOURNAL ARTICLE
(no author information available yet)
Background: Knee instability can arise from various causes and conditions such as neuromuscular disease, central nervous system conditions, and trauma. For people with knee instability, knee orthosis devices are prescribed to help with standing, walking, and performing tasks. We conducted a health technology assessment of stance-control knee-ankle-foot orthoses (SCKAFOs) for people with knee instability, which included an evaluation of the effectiveness, safety, and budget impact of publicly funding SCKAFOs, as well as patient preferences and values...
2021: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/34422143/istent-for-adults-with-glaucoma-a-health-technology-assessment
#17
JOURNAL ARTICLE
(no author information available yet)
Background: Glaucoma is a condition that causes progressive damage to the optic nerve, which can lead to visual impairment and potentially to irreversible blindness. The iStent and iStent inject are devices implanted in the eye during a type of minimally invasive glaucoma surgery (MIGS) to reduce intraocular pressure by increasing trabecular outflow by bypassing the trabecular meshwork. We summarized two health technology assessments and additional recent publications that evaluated iStent for people with glaucoma, including effectiveness, safety, cost-effectiveness, the budget impact of publicly funding iStent, and patient preferences and values...
2021: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/34211617/nonthermal-endovenous-procedures-for-varicose-veins-a-health-technology-assessment
#18
JOURNAL ARTICLE
(no author information available yet)
BACKGROUND: Varicose veins are part of the spectrum of chronic venous disease and are a sign of underlying chronic venous insufficiency. Treatments to address varicose veins include surgical vein removal under general anesthesia, or endovenous laser (EVLA) or radiofrequency ablation (RFA) under tumescent anesthesia. Two newer nonthermal endovenous procedures can close veins without any tumescent anesthesia, using either mechanochemical ablation (MOCA, a combination of mechanical and chemical techniques) or cyanoacrylate adhesive closure (CAC)...
2021: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/34211616/skin-substitutes-for-adults-with-diabetic-foot-ulcers-and-venous-leg-ulcers-a-health-technology-assessment
#19
JOURNAL ARTICLE
(no author information available yet)
Background: Wounds may be caused in a variety of ways. Some wounds are difficult to heal, such as diabetic foot ulcers and venous leg ulcers. We conducted a health technology assessment of skin substitutes for adults with neuropathic diabetic foot ulcers and venous leg ulcers, which included an evaluation of effectiveness, safety, cost-effectiveness, the budget impact of publicly funding skin substitutes, and patient preferences and values. Methods: We performed a systematic literature search of the clinical evidence...
2021: Ontario Health Technology Assessment Series
https://read.qxmd.com/read/34188733/prostatic-artery-embolization-for-benign-prostatic-hyperplasia-a-health-technology-assessment
#20
JOURNAL ARTICLE
(no author information available yet)
Background: Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate that commonly affects older people with prostates and may lead to obstructive urinary symptoms. Symptoms may initially be mild but tend to worsen over time. Prostatic artery embolization (PAE) is an endovascular procedure to treat BPH, wherein an interventional radiologist inserts a catheter into the patient to inject tiny particles intended to reduce blood flow to the enlarged prostate, causing it to shrink in size...
2021: Ontario Health Technology Assessment Series
journal
journal
42808
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.